Name (Synonyms) | Correlation | |
---|---|---|
drug279 | Cambridge Validated Viral Detection Method Wiki | 0.71 |
drug1124 | Radiological Detection Wiki | 0.71 |
drug918 | Normobaric oxygen therapy Wiki | 0.71 |
drug1017 | Placebo (PBO) Wiki | 0.71 |
drug641 | Hyperbaric oxygen therapy Wiki | 0.71 |
drug23 | 300 mg EIDD-2801 Wiki | 0.71 |
drug1178 | SAMBA II (Diagnostic for the Real World) Wiki | 0.71 |
drug1089 | Public Health England Gold Standard Wiki | 0.71 |
drug1016 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D000208 | Acute Disease NIH | 0.71 |
D014777 | Virus Diseases NIH | 0.09 |
D003141 | Communicable Diseases NIH | 0.07 |
D007239 | Infection NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
This is a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 versus placebo as measured by infectious virus detection in symptomatic adult outpatients with COVID-19
Description: The distribution of days until first non-detectable SARS-CoV-2 in nasopharyngeal (NP) swabs will be estimated for each randomized arm (drug versus placebo), using Kaplan-Meier methods with a corresponding stratified log-rank test (to account for the "early" versus "late" time from symptom onset randomization strata)
Measure: Virologic Efficacy Time: 28 daysDescription: Measure the safety and tolerability of EIDD-2801 by estimating in the randomization arm the probability of 1) any adverse events (AEs) leading to early discontinuation of blinded treatment (active or placebo), 2) study drug-related discontinuation of treatment, 3) new grade 3 or higher AE (not already present at baseline), and 4) study drug-related new grade 3 or higher AE. The cumulative probability of each safety and each tolerability endpoint (4 endpoints) by using the Kaplan-Meier approach and stratified log-rank test.
Measure: Number of Participants with any Adverse Events (AEs) as Assessed by Kaplan Meier Approach Time: 28 daysDescription: Measure the safety and tolerability of EIDD-2801 by estimating the occurrence of Grade 2 or higher AE and drug related AEs by using the Kaplan-Meier approach and stratified log-rank test.
Measure: Number of Participants With any Adverse Events (AEs), Grade 2 or higher as Assessed by Kaplan Meier Approach Time: 28 daysDesigned as a single center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.
Description: Achievement of undetectable SARS-CoV-2 RNA by Day 5 in nasopharyngeal (NP) swabs by quantitative reverse transcription polymerase chain reaction (qPCR) after administration with EIDD-2801
Measure: Number of Participants that achieve Virologic Clearance after oral administration of EIDD-2801 Time: 28 daysDescription: Incidence of Serious Adverse Events in subjects receiving EIDD-2801
Measure: Number of Participants With any Serious Adverse Events(SAEs) as assessed by DAIDS Time: 28 daysDescription: Incidence of Adverse Events in subjects receiving EIDD-2801
Measure: Number of Participants With any Adverse Events(AEs) as assessed by DAIDS Time: 28 days